Yichan Zhang

Jun 7, 2023 | frontiersin.org | Yichan Zhang |Andreas M. Beyer |Kalliopi Keramida |Leilei Cheng

1. Introduction For decades, anticancer therapies, such as anthracyclines, cyclophosphamide and trastuzumab, have found broad applications in hematological malignancies and solid tumors, and greatly benefited many patients. However, cardiac injury is the major adverse effect of anticancer treatment (1–3). Many cancer survivors experience not only congestive heart failure, but also myocardial ischemia, thromboembolism, hypertension and arrhythmias that affect their quality of life (1, 4).